BiotechTube

Ublituximab + Teriflunomide + Oral Placebo + IV Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Multiple Sclerosis (RMS)

Conditions

Relapsing Multiple Sclerosis (RMS)

Trial Timeline

Sep 19, 2017 → Nov 6, 2020

NCT ID
NCT03277261

About Ublituximab + Teriflunomide + Oral Placebo + IV Placebo

Ublituximab + Teriflunomide + Oral Placebo + IV Placebo is a phase 3 stage product being developed by TG Therapeutics for Relapsing Multiple Sclerosis (RMS). The current trial status is completed. This product is registered under clinical trial identifier NCT03277261. Target conditions include Relapsing Multiple Sclerosis (RMS).

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Multiple Sclerosis (RMS) were approved

Approved (20) Terminated (2) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Interferon beta-1aMerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Rebif® (clone 484-39)MerckApproved
✅RebifMerckApproved
✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03277261Phase 3Completed
NCT03277248Phase 3Completed

Competing Products

20 competing products in Relapsing Multiple Sclerosis (RMS)

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
27
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
dirucotide + placeboEli LillyPhase 2/3
38
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRNMerckPhase 3
40
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Teriflunomide + EvobrutinibMerckPhase 3
32
Cladribine + Placebo + Microgynon®MerckPhase 1
29